GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
77.06
-0.20 (-0.26%)
As of 11:49AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close77.26
Open77.11
Bid77.00 x 800
Ask77.00 x 1300
Day's Range76.95 - 77.76
52 Week Range64.27 - 89.54
Volume1,299,092
Avg. Volume7,204,314
Market Cap100.198B
Beta1.39
PE Ratio (TTM)29.31
EPS (TTM)2.63
Earnings DateJul 25, 2018
Forward Dividend & Yield2.28 (3.03%)
Ex-Dividend Date2018-06-14
1y Target Est86.00
Trade prices are not sourced from all markets
  • Sure, these corporate workforces make the big bucks, but do they deserve it?
    American City Business Journals2 hours ago

    Sure, these corporate workforces make the big bucks, but do they deserve it?

    Who has the most productive workforce in the Bay Area, and how much does each employee rake in per year, on average?

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit4 hours ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • 4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?
    Motley Foolyesterday

    4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?

    A game of musical chairs is coming to the HIV market.

  • 3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018
    Motley Fool2 days ago

    3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018

    Forget what's happened so far in 2018. These big pharma stocks look like great picks for the rest of the year.

  • 3 Biotech Stocks With Big News Coming in NASH
    Motley Fool3 days ago

    3 Biotech Stocks With Big News Coming in NASH

    The next big market for biopharma could be nonalcoholic steatohepatitis, so upcoming data from these companies could be market-moving.

  • Business Wire4 days ago

    Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018

    Gilead Sciences, Inc. (GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes. At 5:00 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2018 and provide a general business update. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the conference ID 8988927 to access the call.

  • Investopedia4 days ago

    Gilead's Hot Stock May Have Further to Rise

    Gilead Sciences Inc. ( GILD) stock may be finally starting to show a revival after three years of sharp declines, dragging the stock down by over 30%. Options traders are betting the rally in Gilead will continue as well, and they see the stock rising to about $82 by the middle of August. The longer-term outlook for Gilead still proves to be questionable with the company still facing declining revenues as it rebuilds its drug pipeline.

  • InvestorPlace5 days ago

    3 Real Risks That Could Make You Reconsider Buying Celgene Stock

    Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • If You're Thinking About Buying Gilead Sciences Stock, Now's the Time to Do It
    Motley Fool5 days ago

    If You're Thinking About Buying Gilead Sciences Stock, Now's the Time to Do It

    There's no time like the present to buy this big biotech stock.

  • Investopedia6 days ago

    Top 5 Biotech Stocks for 2018

    Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.

  • Benzinga6 days ago

    3 Stocks With Bullish Setups For The Rest Of The Week

    The following four stocks are currently in the midst of uptrends according to VantagePoint, an AI charting platform that uses intermarket analysis and artificial intelligence to predict future price action 1-3 days in advance. The blue line is a predicted moving average that forecasts a stock's moving average two days out. Ford Motor Company (NYSE: F) was on a clear downtrend starting on June 13, but that looks to have ended for now as the stock has bounced off the $11 level.

  • The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna
    Zacks7 days ago

    The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna

    The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna

  • InvestorPlace7 days ago

    Trade of the Day: Gilead Sciences (GILD)

    To receive further updates on this Gilead Sciences (NASDAQ:GILD) trade, sign up for a risk-free trial of Maximum Options today. XLF bounced briefly earlier this week, but it remains below all of its major moving averages.

  • Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy
    Business Wire8 days ago

    Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy

    Kite, a Gilead Company (GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy. In this position, Mr. Amoroso will have responsibility for Kite’s commercial organization including sales, marketing, market access, and healthcare provider and patient services.

  • Top Research Reports for Mastercard, Gilead & Goldman Sachs
    Zacks8 days ago

    Top Research Reports for Mastercard, Gilead & Goldman Sachs

    Top Research Reports for Mastercard, Gilead & Goldman Sachs

  • Investopedia8 days ago

    4 Biotechs on Verge of Big Breakouts

    The large-cap biotech stocks have been left in the dust this year with the iShares Nasdaq Biotechnology ETF ( IBB) rising by only 8.7%. This, by most standards, is a healthy gain compared to the S&P 500 rise of only 3%. Signs are emerging that the larger-cap biotechs are poised to break out in the near term, and that could send stocks like Celgene Corp. ( CELG), Gilead Sciences, Inc. ( GILD), Amgen Inc. ( AMGN) and Alexion Pharmaceuticals, Inc. ( ALXN) much higher.

  • Why Biotech Stocks Rallied on Biogen's Alzheimer's Test
    Zacks11 days ago

    Why Biotech Stocks Rallied on Biogen's Alzheimer's Test

    Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.

  • Investopedia11 days ago

    7 Stocks That Can Lead The Market Longterm

    In the search for investments with long-term growth potential, an increasing number of funds, and fund managers, are focusing on companies that score high on so-called Environmental, Social and Governance (ESG) criteria.

  • TheStreet.com11 days ago

    Biotech Stocks Rally on Biogen's Landmark Test

    The NASDAQ Biotechnology Index rose about 3% in midday trading Friday to 3,636.45, the highest level since February. underperforming the overall NASDAQ Index in the past year, investors might be recognizing the hidden value of the firms' drug research and development, says Steve Chesney, an analyst for Atlantic Equities in London who covers large cap biotech firms worth more than $60 billion. Celgene, a biotechnology company which develops anti-inflammatory drugs for cancer and other diseases rose around 2% to $82.09 in early afternoon trading.

  • TheStreet.com11 days ago

    Gilead Sciences Is Displaying a Bullish Long-Term Pattern

    The daily chart looks like it could use more development but the weekly bar chart shows us a strong bottom formation. In the daily bar chart of GILD, below, you can see a wide swinging market. Now you have to really look at the daily On-Balance-Volume (OBV) line.

  • ACCESSWIRE11 days ago

    Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio

    NEW YORK, NY / ACCESSWIRE / July 6, 2018 / U.S. markets rose Thursday on the strength of the technology sector, yet investors appear to be apprehensive as the U.S. prepare to place tariffs on Chinese goods. ...

  • Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More
    Zacks12 days ago

    Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

    Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.

  • Nasdaq turns negative as tech stocks give up earlier gains
    Yahoo Finance Video7 days ago

    Nasdaq turns negative as tech stocks give up earlier gains

    Yahoo Finance’s Seana Smith and Jared Blikre with up-to-the-minute market analysis and the biggest headlines in midday trading Tuesday.

  • Drug pricing debate could heat up in July
    CNBC Videos12 days ago

    Drug pricing debate could heat up in July

    CNBC's Meg Tirrell reports on drug prices and hikes that have already occurred this month. With Michael Yee, Jefferies.